These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial. Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW; Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548 [TBL] [Abstract][Full Text] [Related]
9. mTOR, a Potential Target to Treat Autism Spectrum Disorder. Sato A CNS Neurol Disord Drug Targets; 2016; 15(5):533-43. PubMed ID: 27071790 [TBL] [Abstract][Full Text] [Related]
10. Treatment of autistic spectrum disorder with insulin-like growth factors. Riikonen R Eur J Paediatr Neurol; 2016 Nov; 20(6):816-823. PubMed ID: 27562096 [TBL] [Abstract][Full Text] [Related]
11. The α7 nicotinic acetylcholine receptor: A mediator of pathogenesis and therapeutic target in autism spectrum disorders and Down syndrome. Deutsch SI; Burket JA; Urbano MR; Benson AD Biochem Pharmacol; 2015 Oct; 97(4):363-377. PubMed ID: 26074265 [TBL] [Abstract][Full Text] [Related]
12. Treating a Child With Mental Illness. Ito S Clin Pharmacol Ther; 2018 Oct; 104(4):592-594. PubMed ID: 30222188 [TBL] [Abstract][Full Text] [Related]
13. Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. Lacivita E; Perrone R; Margari L; Leopoldo M J Med Chem; 2017 Nov; 60(22):9114-9141. PubMed ID: 29039668 [TBL] [Abstract][Full Text] [Related]
14. Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date. Fung LK; Hardan AY CNS Drugs; 2015 Jun; 29(6):453-63. PubMed ID: 26104862 [TBL] [Abstract][Full Text] [Related]
15. Metabotropic functions of the NMDA receptor and an evolving rationale for exploring NR2A-selective positive allosteric modulators for the treatment of autism spectrum disorder. Burket JA; Deutsch SI Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():142-160. PubMed ID: 30481555 [TBL] [Abstract][Full Text] [Related]
16. Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf/J mice: Contribution of central and peripheral mechanisms. Cristiano C; Pirozzi C; Coretti L; Cavaliere G; Lama A; Russo R; Lembo F; Mollica MP; Meli R; Calignano A; Mattace Raso G Brain Behav Immun; 2018 Nov; 74():166-175. PubMed ID: 30193877 [TBL] [Abstract][Full Text] [Related]
17. Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder. Tilot AK; Frazier TW; Eng C Neurotherapeutics; 2015 Jul; 12(3):609-19. PubMed ID: 25916396 [TBL] [Abstract][Full Text] [Related]
18. Clinical potential of oxytocin in autism spectrum disorder: current issues and future perspectives. Benner S; Yamasue H Behav Pharmacol; 2018 Feb; 29(1):1-12. PubMed ID: 28857771 [TBL] [Abstract][Full Text] [Related]
19. The Role of Vitamins in Autism Spectrum Disorder: What Do We Know? Bjørklund G; Waly MI; Al-Farsi Y; Saad K; Dadar M; Rahman MM; Elhoufey A; Chirumbolo S; Jóźwik-Pruska J; Kałużna-Czaplińska J J Mol Neurosci; 2019 Mar; 67(3):373-387. PubMed ID: 30607900 [TBL] [Abstract][Full Text] [Related]
20. Current status of biological treatment options in Autism Spectrum Disorder. Eapen V; Nicholls L; Spagnol V; Mathew NE Asian J Psychiatr; 2017 Dec; 30():1-10. PubMed ID: 28704714 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]